Celyad (Formally Known as Cardio3 BioSciences)

140 articles about Celyad (Formally Known as Cardio3 BioSciences)

• Cardio3 BioSciences Awarded Preferred Access Rights To Mayo Clinic Center For Regenerative Medicine Portfolio

  10/8/2014

• Cardio3 BioSciences Announces New Business Development Strategy To Broaden Its Product Pipeline

  10/1/2014

• Cardio3 BioSciences Receives Approval For The Continuation Of Its Chart-1 Phase III Clinical Trial From The DSMB

  9/15/2014

• Cardio3 BioSciences Reports 2014 Half Year Financial Results And Business Update

  8/22/2014

• Cardio3 BioSciences Announces Secondary Placement With New Institutional Investors

  7/9/2014

• Cardio3 BioSciences To Enroll The 120th Patient For Its CHART-1 Study

  7/7/2014

• Cardio3 BioSciences Announces Completion Of Its Capital Increase Of €25 Million At €44 Per Share

  7/1/2014

• Cardio3 BioSciences Teams Up With Medisun International To Create Cardio3 Biosciences Asia Holdings Ltd, A Joint Venture Aimed At Conducting Pivotal Clinical Programs In Greater China

  6/16/2014

• Cardio3 BioSciences Announces A Capital Increase Of €25 Million At €44 Per share.

  6/16/2014

• Cardio3 BioSciences, A European Biopharmaceutical Company, Now Covered By Edison Investment Research

  1/8/2014

• Cardio3 BioSciences Announces Participation At The 32nd Annual JP Morgan Healthcare Conference In San Francisco

  12/30/2013

• Cardio3 BioSciences Announces Q3 2013 Business Update And Authorization To Enroll Patients In Poland In Its Chart-1 Phase III Clinical Trial

  11/13/2013

• Cardio3 BioSciences Receives Authorization to Enroll Patients in Italy in Its Phase III Clinical Trial CHART-1

  10/23/2013

• Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Walloon Brabant

  10/17/2013

• Cardio3 BioSciences to Participate at the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14

  10/14/2013

• Cardio3 BioSciences Strengthens Management Team by Appointing Dr. Gaëtane Metz as Chief Operating Officer

  10/7/2013

• Cardio3 BioSciences's Recent $29 Million Biotech IPO Relied Heavily on Questionable Research

  7/9/2013

• Belgian Heart Drug Firm Cardio3 BioSciences Launches IPO

  6/21/2013

• Belgian Heart Drug Firm Cardio3 BioSciences Plans to IPO in Paris, Brussels

  6/5/2013

• Cardio3 BioSciences Raises $24.9 Million Through a Private Placement

  5/8/2013